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advisor,Obstacles are those frightful things you see
when you take your eyes off your goal.—Henry Ford (1)
Biomarker, a naturally occurring mole-
cule, gene, or characteristic by which a
particular pathological or physiological
process, disease, etc. can be identiﬁed.—Oxford Dictionary (2)SEE PAGE 37I n addition to being very powerful for analyzingvolumes, function, morphology, mass, ﬂow,perfusion, and more, cardiac magnetic resonance
(CMR) has become an indispensable tool for myocar-
dial tissue characterization. During a magnetic reso-
nance imaging scan, short high-frequency pulses
interfere with the magnetic equilibrium of protons,
which quickly recovers as protons “relax.” The relax-
ation process has 2 major time components: 1) T1, the
spin-lattice (longitudinal) relaxation time; and 2) T2,
the spin-spin (transversal) relaxation time. Impor-
tantly, these times are modiﬁed by the immediate
molecular environment and thus can be understood
as basic quantitative markers for the behavior of
myocardial tissue in a strong magnetic ﬁeld and ulti-
mately for myocardial tissue composition. Native
(i.e., without contrast agents) T1 is increased in the
presence of myocardial edema and reduced in the
presence of myocardial iron or fat, whereas after
administration of a gadolinium-based (paramagnetic)
contrast agent, T1 is shortened in myocardium with
increased interstitial space, such as scar, diffuse
ﬁbrosis, and inﬁltration. T1 can be presented as aals published in JACC: Cardiovascular Imaging reﬂect the views of
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for all clinical applications where an abnormality of
the myocardial tissue is expected, especially in noni-
schemic cardiomyopathies. Because the degree of T1
deviation correlates with the extent of the tissue ab-
normality (e.g., a more severe edema will cause a
more extensive T1 prolongation), speciﬁc thresholds
may be applicable to differentiate disease severity
or stage.
Approximately 30 years after Raymond Dama-
dian’s ﬁrst report on T1 and T2 relaxation for detect-
ing tumors, the ﬁrst human myocardial T1 maps (i.e.,
a color-coded map presentation of myocardial relax-
ation times) was reported in patients with acute
myocardial infarction (3).In this issue of iJACC, Hinojar et al. (4) report the
use of T1 mapping for differentiating acute from
convalescent myocarditis. In 165 patients, they per-
formed native (i.e., noncontrast-enhanced) T1 map-
ping at 1.5-T and 3.0-T early and 6 months after
clinical onset of disease. Compared with 40 control
subjects, values >5 SD above normal values in controls
were associated with acute myocarditis, whereas
values between 2 SD and 5 SD were found 6 months
later. In the convalescent stage, an abnormal signal in
late gadolinium enhancement (LGE) images, if pre-
sent, further added diagnostic value. There are some
important observations: Native T1 clearly out-
performed LGE in detecting acute myocarditis
(sensitivity 98% vs. 72%), whereas the convalescent-
stage LGE was more sensitive (86% vs. 76%); even
better than LGE alone, however, was a combination of
native T1 and LGE (95% vs. 86%). On a multivariate
analysis, native T1 remained the only variable of sta-
tistical signiﬁcance. Differences and accuracies were
consistent between ﬁeld strengths, albeit the diag-
nostic performance tended to be better at 3.0-T.
The data conﬁrm a previous report by Ferreira et al.
(5), who found a sensitivity of 90% (vs. 72% for LGE)
TABLE 1 Current Status of Native T1 Mapping
Potential clinical applications
Dilated and hypertrophic cardiomyopathy (6)
Myocarditis (4)
Lupus erythematosus (7)
Amyloidosis (8)
Ischemic heart disease (9)
Current limitations
Susceptibility and motion artifacts (in 5%–10% of native T1 maps) (12)
Variability between MR systems and ﬁeld strengths (12)
Variability between CMR sequences (13)
Variability of evaluation algorithms and software
Unclear impact of tissue pathology other than edema
CMR ¼ cardiac magnetic resonance; MR ¼ magnetic resonance.
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48in patients with acute myocarditis and thus indicate
that native T1 mapping with predeﬁned thresholds
may be an alternative to the current diagnostic CMR
criteria (Lake Louise Criteria).
The discrimination of acute from convalescent
myocarditis by 2 different thresholds (signal intensity
of >5 SD and signal intensity of <5 SD and >2 SD
above mean) is a very interesting concept, although
the data are mainly associative. There are also some
limitations to a generalized applicability of the data.
The high incidence of elevated troponin indicates
that most of the myocarditis cases were necrotizing
and thus may be more severe than in other pop-
ulations. As the deﬁnition of myocarditis was based
on apparent clinical grounds, the added value of CMR
in less severe cases remains to be deﬁned.
Finally, the predictive value of native T1 for func-
tional outcome, which was found for T2, should be
investigated.
Native T1 mapping, although still evolving, has
already demonstrated the ability to provide incre-
mental diagnostic information in several clinical en-
tities (Table 1) (5–9), where abnormalities were related
to acute injury, ﬁbrous degeneration, and inﬁltration.
Native T1 does not require the injection of contrast
agents and thus has advantages with respect to patient
safety and cost. Although the risk of adverse events
associated with gadolinium injection is much less than
commonly perceived (0.17%) and serious concerns about
systemic ﬁbrosis are no longer warranted, side effectssuch as nausea, headaches, and, very rarely, allergic re-
actions may occur. Image acquisition must be performed
during speciﬁc time windows after injection and cannot
be immediately repeated. Thus, although the addition of
contrast agents may be necessary for assessing extracel-
lular volume fraction or hyperemia associated with
inﬂammation, a native technique may be sufﬁcient in
suspected acute myocarditis.
T1 mapping is rapidly evolving, and there are
published recommendations for terms and its stan-
dardized use (10). Reference values have been pub-
lished for different scanners and commonly used ﬁeld
strengths (11,12). It, therefore, can be used by expe-
rienced centers in the absence of better disease
markers (e.g., suspected diffuse ﬁbrosis). However,
there are still limitations that should be kept in mind
(Table 1), as it is sensitive to variability caused by
speciﬁc acquisition hardware and software. CMR
centers, therefore, should still establish local datasets
for normal T1 values.
Future clinical researchmust investigate the utility,
efﬁcacy, efﬁciency, and cost-efﬁciency of native (and
post-contrast) T1 mapping in various clinical contexts.
Furthermore, studies are needed to demonstrate the
speciﬁc impact of myocardial tissue pathology on
T1 and T2. This may also require validation against
histopathology, although this is a methodologically
challenging gold standard. Eventually we will also
have to verify a positive impact of myocardial relaxa-
tion time mapping on patient outcome.
The paper by Hinojar et al. (4) indicates the clinical
utility of native T1 mapping for monitoring tissue
changes after acute disease. It underscores the
potential of myocardial relaxation time mapping to
attain a noninvasive assessment of tissue pathology.
As the ejection fraction (with all its limitations) is
used as a single number to describe a global systolic
functional status of the heart, native T1 mapping used
within a clinical context is about to emerge as a novel
biomarker for the status of the myocardium.
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